LDL-aféresis en la hipercolesterolemia familiar

1. Díaz Díaz, José Luis
2. Argüeso Armesto, Rosa
3. Pose Reino, Antonio
4. Fernández Álvarez, Ovidio
5. Toro Santos, Manuel de
6. Suárez Tembra, Manuel A.
7. Rodríguez González, A

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openDialnet dialnet

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Galicia Clínica

Abstract

Familial hypercholesterolemia (HF) is an inherited disorder of lipid metabolism, an autosomal dominant disease, caused by a multitude of Low Density Lipoproteins receptor (LDLR) gene mutations, characterized by high levels of LDL cholesterol levels beginning at birth (double those of the general population) and incidence of cardiovascular disease, often premature. In some heterozygous FH (prevalence 1/500) and homozygous (1/1000000) coronary heart disease and degenerative aortic valve disease appear in the first or second decade of life. In those cases, early and intensive lipid lowering treatment often combined is mandatory, although partially effective. LDL-aferesis or hepatic transplant are additional stra tegies while expecting gene therapy. After three decades of use, LDL-aferesis has shown to be efective and security as hypolipemic treatment reducing cardiovascular morbidity and mortality.

Data source: Dialnet